menu
    • menu
    [{"orgOrder":0,"company":"Pharmaceutical Project Solutions, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cocaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"Pharmaceutical Project Solutions, Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Pharmaceutical Project Solutions, Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pharmaceutical Project Solutions, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Cocaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Undisclosed","graph2":"Phase III","graph3":"Lannett Company, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Lannett Company, Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lannett Company, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Cocaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Lannett Company, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Lannett Company, Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lannett Company, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cocaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Lannett Company, Inc.","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Lannett Company, Inc. \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Lannett Company, Inc. \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Cocaine HCl

    Menu

    Cocaine HCl

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lannett Company, Inc.

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Lannett Company, Inc.

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cocaine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lannett Receives Fda Approval To Manufacture Numbrino® At Seymour Plant

                            Details : Numbrino™ (Cocaine Hydrochloride Nasal Solution) company's branded topical anesthetic product for the induction of local anesthesia of the mucous membranes when performing diagnostic procedures and surgeries on or through the nasal cavities in adults.

                            Product Name : Numbrino

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 21, 2022

                            Lead Product(s) : Cocaine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Pharmaceutical Project Solutions, Inc

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Pharmaceutical Project Solutions, Inc

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cocaine Hydrochloride

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetics, Safety, and Tolerability Study of GOPRELTO® Nasal Solution

                            Details : Cocaine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Otorhinolaryngologic Diseases.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 10, 2021

                            Lead Product(s) : Cocaine Hydrochloride

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Lannett Company, Inc.

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Lannett Company, Inc.

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cocaine Hydrochloride

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Topical Application of Cocaine HCl 4%, or 10%, or Placebo Solution in Local (Topical) Anesthesia

                            Details : Cocaine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Otorhinolaryngologic Diseases.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 17, 2015

                            Lead Product(s) : Cocaine Hydrochloride

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Lannett Company, Inc.

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Lannett Company, Inc.

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cocaine Hydrochloride

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Topical Application of Cocaine HCl 4% and 10% on Safety and Efficacy in Local (Topical) Anesthesia

                            Details : Cocaine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 11, 2012

                            Lead Product(s) : Cocaine Hydrochloride

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth